Algoblan et al. (2019) |
Saudi Arabia: outpatient clinics including
private clinics and governmental hospitals |
33 to 40 |
6/2017 –
11/2017 |
Patient survey |
Isotretinoin |
NS |
28 |
Mitchell et al. (1995) |
USA: Telephone or mailed survey |
12 to 59 |
1/1989 - 12/1993 |
Patient survey |
Isotretinoin |
Pregnancy Prevention
Program for isotretinoin |
25 |
Cheetham et al. (2006) |
USA: Kaiser Permanente (a national, non-profit,
managed care organization) |
NS |
2000 - 2004 |
Medical records |
Isotretinoin |
Kaiser Permanente Southern California isotretinoin risk
management program |
28 |
Rao et al. (2000) |
USA: Telephone or mailed survey |
NS |
1990 - 1993 |
Patient survey |
Isotretinoin |
NS |
28 |
Uusküla et al. (2018) |
Estonia: The Estonian Health Insurance Fund
(EHIF) |
15 to 45 |
1/2012 - 10/2016 |
Medical records |
Isotretinoin |
NS |
31 |
Pinheiro et al. (2013) |
USA: IMS Health, Vector One®: Data Extract Tool
(DET) |
13 to 45 |
3/2004 - 2/2008 |
Medical records |
Isotretinoin |
iPledge |
28 |
Entezari-Maleki et al. (2012) |
Iran: Institutional community pharmacy
service affiliated with the college of pharmacy, Tehran University of
Medical Sciences |
NS |
7/2007 - 1/2008 |
Patient survey and medical
records |
Isotretinoin |
NS |
33 |
Lelubre et al. (2018) |
Belgium: Questionnaires delivered online by
email |
NS |
12/2014 - 10/2015 |
Patient survey |
Isotretinoin |
Pregnancy Prevention Program for isotrentinoin |
29 |
Teichert et al. (2010) |
Netherlands: The Dutch Foundation for
Pharmaceutical Statistics (SFK) |
15 to 45 |
1/2005 - 12/2008 |
Medical
records |
Isotretinoin |
The Dutch pregnancy prevention program |
31 |
Boucher and Beaulac-Baillargeon (2006) |
Canada: Telephone interview |
≥14 |
11/2003 - 7/2004 |
Patient survey |
Isotretinoin |
NS |
30 |
Crijns et al. (2012) |
Netherlands: IADB (a database, containing
information of prescribed medication in public pharmacies in the
Netherlands) |
15 to 49 |
1999 - 2006 |
Medical records |
Isotretinoin |
NS |
27 |
Ozyurt and Kaptanoglu (2015) |
Turkey: Dermatology clinic in a Hospital |
14 to 35 |
1/2012 for 18 months |
Patient survey |
Isotretinoin |
NS |
24 |
Tsur et al. (2008) |
Israel: Drug Consultation Centre |
16 to 45 |
7/2005 - 10/2005 |
Patient survey |
Isotretinoin |
NS |
31 |
Brinker et al. (2005) |
USA: A novel pharmacy compliance survey and an
ongoing, voluntary survey |
15 to 45 |
10/2002 - 4/2003 |
Patient survey |
Isotretinoin |
System to Manage Accutane-Related Teratogenicity
(SMART) program |
33 |
Werner et al. (2014) |
USA: Urban community via flyers displayed on
college campuses, at dermatology clinics, and at student health
facilities |
14 to 45 |
1/2012 - 9/2012 |
Patient survey |
Isotretinoin |
iPledge |
32 |
Hogan et al. (1988) |
Canada: Dermatology clinic and general
practitioner clinic |
NS |
4/1983 - 3/1985 |
Patient survey and medical
records |
Isotretinoin |
NS |
24 |
Bhakta et al. (2015) |
USA: Outpatient Neurology Clinics in a hospital |
15 to 44 |
7/2011 - 6/2012 |
Medical records |
Anti-epileptic drugs
(phenobarbital, primidone, phenytoin, fosphenytoin, ethosuximide,
carbamazepine, sodium valproate, and topiramate) |
NS |
25 |
Wieck et al. (2007) |
UK: Psychiatric departments of three teaching
hospitals |
16 to 47 |
11/2004 - 10/2005 |
Medical records |
Sodium
valproate, semisodium valproate or carbamazapine |
National Institute
for Health and Clinical Excellence for epilepsy (2004) |
24 |
Bell et al. (2002) |
UK: General practices and outpatient department of
hospital consultants (neurologists, paediatricians and paediatric
neurologists), in addition to mailed questionnaire |
14 to 55 |
2000 |
Patient survey |
Anti-epileptic drugs |
Services for patients with
epilepsy: report of a CSAG Committee chaired by Professor Alison Kitson |
28 |
Langan et al. (2013) |
UK: Secondary care psychiatric contacts |
16 to
50 |
2002 - 2005 |
Medical records |
Sodium valproate, carbamazepine,
lamotrigine and topiramate |
NS |
31 |
Bosak et al. (2019) |
Poland: A university epilepsy clinic |
16 to 49 |
8/2017 - 8/2018 |
Patient survey and medical records |
Anti-epileptic
drugs |
NS |
28 |
Leverenz et al. (2019) |
USA: Rheumatology Clinic, Dermatology Clinics
and an online community of people living with inflammatory arthritis |
≤40 |
2015 - 2017 |
Patient survey |
Methotrexate, anti-TNF (infliximab,
adalimumab, etanercept, golimumab, or certolizumab) and novel
medications (abatacept, apremilast, rituximab, tocilizumab, tofacitinib,
secukinumab, and ustekinumab) |
NS |
30 |
Yazdany et al. (2011) |
USA: Academic rheumatology offices , community
rheumatology offices, and nonclinical sources, including patient support
groups and conferences and other forms of media |
≤45 |
2008 - 2009 |
Patient survey |
Methotrexate, mycophenolate mofetil, azathioprine,
cyclosporine, tacrolimus, leflunomide, cyclophosphamide, or biologic
agent |
NS |
33 |
Ferguson et al. (2016) |
USA: Academic and community practices , lupus
support groups and conferences , and newsletters, websites and other
forms of publicity |
≤45 |
2003 - 2010 |
Patient survey |
Azathioprine,
mycophenolate, methotrexate, cyclosporine, leflunomide,
cyclophosphamide, rituximab, abatacept, or belimumab |
NS |
31 |
Banas et al. (2014) |
Poland: NS |
NS |
NS |
Patient survey |
Leflunomide |
NS |
26 |
Paton et al. (2018) |
UK: Mental health provider organisations |
≤ 50 |
|
Medical records |
Sodium valproate |
NICE guideline for bipolar
disorder (NICE 2014) |
25 |
Gotlib et al. (2016) |
USA: A tertiary medical centre |
15 to 49 |
1/2013 - 7/2014 |
Medical records |
Sodium valproate |
American
Psychiatry Association, American Congress of Obstetrics and
Gynaecologists, National Institute for Health and Care Excellence and
American Academy of Neurology and American Epilepsy Society |
29 |
Mulryan et al. (2018) |
Ireland: Irish mental health service |
18 to 49 |
42370 |
Medical records |
Sodium valproate |
NS |
28 |
Atturu and Odelola (2015) |
UK: Adult Psychiatric service |
18 to 45 |
2005 - 2012 |
Medical records |
Sodium valproate |
Bipolar disorder: The
management of bipolar disorder in adults, children and adolescents, in
primary and secondary care (NICE) 2006 |
29 |
Brandenburg et al. (2017) |
USA: Mandatory and voluntary surveys of the
REMS program |
NS |
6/2012 - 6/2013 |
Patient survey |
Thalidomide and
lenalidomide |
REMS for thalidomide and lenalidomide |
29 |
Castaneda et al. (2008) |
USA: REMS |
females of child bearing potential |
12/2005 - 12/2007 |
Patient survey |
Lenalidomide |
RevAssist® |
29 |
Chave et al. (2001) |
UK: Dermatologists |
NS |
36434 |
Physician
questionnaire |
Thalidomide |
NS |
25 |
Raguideau et al. (2015) |
France: The French national health insurance
database (SNIIRAM), The complementary Universal Health Insurance (CMUc),
and The French hospital discharge database (PMSI) |
15 to 49 |
1/2006 -
12/2013 |
Medical records |
Acitretin |
NS |
27 |
Valle et al. (1998) |
UK: Cancer care hospital |
NS |
|
Patient survey |
Chemotherapy for breast cancer |
NS |
25 |
Shilalukey et al. (1997) |
Canada: Haemoglobinopathy Clinics of a
children’s hospital and a general hospital |
Teenagers |
7/1993 - 7/1994 |
Patient survey |
Deferoxamine and deferiprone |
NS |
25 |
Hayward et al. (2016) |
USA: Children’s Hospital |
12 to 21 |
7/2011 -
6/2015 |
Medical records |
Cyclophosphamide |
NS |
31 |
Landis et al. (2012) |
USA: The National Ambulatory Medical Care Survey
(NAMCS) |
12 to 55 |
1993 - 2008 |
Patient log |
Isotretinoin and oral
contraceptives |
iPledge |
31 |
James et al. (2007) |
UK: A mental health trust |
18 to 45 |
2006 |
Medical records |
Lithium, carbamazepine or sodium valproate |
NS |
26 |
Chang et al. (2018) |
Uganda: Uganda Heart Institute (UHI) |
15 to 59 |
NS |
Patient survey |
Warfarin |
NS |
35 |
Steinkellner et al. (2010) |
USA: Database from Medco Health Solutions,
Inc.(Franklin Lakes, NJ), a pharmacy benefits manager |
18 to 44 |
1/2008 - 6/2009 |
Medical records |
Category X |
FDA, validated by
Micromedex and Clinical Pharmacology ref |
28 |
Schwarz et al. (2007) |
USA: Kaiser Permanente (a health maintenance
organization) |
15 to 44 |
2001 |
Medical records |
Category D or X |
FDA |
30 |
Schwarz et al. (2005) |
USA: The National Ambulatory Medical Care Survey
(NAMCS), an annual survey of non-federal employed, office-based
physicians |
14 to 44 |
1998 - 2000 |
Medical records |
Category D or X |
FDA |
27 |
Goyal et al. (2015) |
USA: National Hospital Ambulatory Medical Care
Survey (NHAMCS) |
14 to 40 |
2005 - 2009 |
Patient survey |
Category D
or X |
FDA |
35 |
Stancil et al. (2016) |
USA: Academic paediatric medical centre |
14 to
25 |
1/2008 - 12/2012 |
Medical records |
Category D or X |
FDA |
30 |
Mody et al. (2015) |
USA: Family medicine at an academic institution |
18 to 45 |
4/2011 - 4/2012 |
Medical records |
Category D or X |
Review
of the category D and X medications in 2012 by a counsellor for
California Teratogen Information Specialists |
32 |
Mody et al. (2015) |
USA: An academic outpatient family medicine clinic |
18 to 45 |
4/2012 - 4/2013 |
Patient survey and medical records |
Category D or X |
FDA |
33 |
Schwarz et al. (2010) |
USA: Pharmacy Benefits Management Database (PBM) |
18 to 45 |
10/2006 - 9/2008 |
Medical records |
Category D or X |
FDA |
35 |
Mager et al. (2018) |
USA: Life plans completed as part of Toledo-Lucas
County Healthy Start |
13 to 44 |
4/2016 - 10/2016 |
Reproductive life
plan |
Category C, D or X |
FDA |
25 |
Fritsche et al. (2011) |
USA: Family medicine clinic |
15 to 44 |
10/2002 - 11/2008 |
Medical records |
Category D or X (paroxetine,
methotrexate or warfarin; selected longer-term tetracyclines
(minocycline or tetracycline); a benzodiazepine (defined as any
medication containing either “azepam” or “azolam”) and any statin
(defined as any medication containing “astatin”) |
FDA |
29 |
Ruiter et al. (2012) |
Netherlands: The Dutch Foundation for
Pharmaceutical Statistics (SFK) |
15 to 45 |
1/2005 - 12/2009 |
Medical
records |
Category D or X and coumarin anticoagulants, phenprocoumon and
acenocoumarol |
Swedish Catalogue of Approved Drugs (FASS), Australian
Drug Evaluation Committee (ADEC) and US Food and Drug Administration
(FDA) |
26 |
Schwarz et al. (2012) |
USA: Academic general internal medicine practice |
18 to 50 |
10/2008 - 4/2010 |
Medical records |
Potential teratogens |
NS |
33 |
Force et al. (2012) |
USA: Family medicine clinics |
18 to 44 |
NS |
Medical records |
Angiotensin-converting enzyme inhibitors,
angiotensin-receptor blockers or statin |
FDA |
28 |
Schwarz et al. (2013) |
USA: Suburban, community-based family practice
and an academic general internal medicine |
18 to 50 |
10/2008 - 6/2009 |
Patient survey and medical records |
Benzodiazepines, antimicrobials
(i.e., doxycycline and fluconazole), angiotensin-converting enzyme
inhibitors and angiotensin-receptor blockers, cardiovascular medications
(e.g., beta-blockers, spironolactone), psychiatric medications (e.g.,
lithium and some antidepressants), and statins |
NS |
32 |
Schwarz et al. (2013) |
USA: The OEF/OIF roster, provided to the VA by
the Department of Defense Manpower Data Center’s (DMDC) Contingency
Tracking System |
≤50 |
7/2008 - 10/2011 |
Patient survey |
Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers,
benzodiazepine or statin |
FDA |
33 |
Martin et al. (2008) |
UK: Hypertension Clinic in a University Hospital |
16 to 45 |
1/2004 - 10/2006 |
Medical records |
Angiotensin converting
enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) |
NS |
22 |